Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37393121/
Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.
Conclusions: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.
Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37345036/
(1) Background: Upfront treatment consolidation with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) has relevantly contributed to achieving durable remissions following induction treatment in multiple myeloma (MM) patients....
Conclusions: Treatment consolidation with TreoMel HDCT demonstrated a promising efficacy and safety profile in our cohort of MM patients and deserves further investigation in prospective studies.
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37316728/
Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase...
Conclusions/Relevance: Isatuximab PK parameters were within the previously reported range, suggesting that VRd does not alter the PK of isatuximab. These data support additional studies of isatuximab in NDMM, such as the Phase 3 IMROZ study (Isa-VRd vs VRd).
Widespread presentation of brown tumors mimicking multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37286908/
Brown tumors or osteitis fibrosa cystica has become a rare presentation of primary hyperparathyroidism in up-to-date clinical practice. Here, we describe a case of longstanding untreated hyperparathyroidism presenting itself with...
Conclusions/Relevance: Here, we describe a case of longstanding untreated hyperparathyroidism presenting itself with brown tumors in a 65-year-old patient. During the diagnostic work-up of this patient, bone SPECT/CT and 18F-FDG-PET/CT revealed multiple widespread osteolytic lesions. Differentiating from other bone tumors such as multiple...
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications - Biomarker Research
Source : https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00502-8
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been made to improve clinical outcomes and to prolong patients' survival in...
Conclusion: In closing, SCS technologies have already revolutionized many aspects of cancer translational research and are prepared to have a greater impact in clinic. As the last decade has seen NGS technologies transform modern oncology, we believe that single-cell methodologies will influence many areas of MM medicine in the same way, and...